SB3221 introduced to add xylazine as a Schedule III controlled substance and reorganize controlled substance schedules (effective date proposed)

Illinois SB3221 (104th GA) proposes amendments to the Illinois Controlled Substances Act to make structural/organizational changes to controlled substance schedules and to add xylazine as a Schedule III controlled substance, with specified exceptions per the bill synopsis. The bill status/synopsis indicates a proposed effective date of January 1, 2027. Compliance relevance: if enacted, xylazine scheduling would trigger controlled substance handling, security, and compliance screening requirements for impacted entities (including veterinary-related stakeholders depending on exemptions).